Published online Oct 15, 2018. doi: 10.4251/wjgo.v10.i10.282
Peer-review started: July 19, 2018
First decision: August 2, 2018
Revised: August 7, 2018
Accepted: August 12, 2018
Article in press: August 13, 2018
Published online: October 15, 2018
Core tip: Peritoneal carcinomatosis (PC) from gastric cancer, along with positive peritoneal cytology, are associated with poor overall outcomes. The treatment of patients with this disease burden has greatly improved and new multimodality treatment regimens have been introduced. Some of these include neoadjuvant laparoscopic heated intraperitoneal chemotherapy and bidirectional therapies like neoadjuvant intraperitoneal and systemic therapy. Appropriate patient selection remains crucial for optimal outcomes but we can be optimistic about the prospects for carefully selected patients with PC from gastric cancer.